secwatch.observer — SEC 8-K summary
======================================

Issuer:     Revolution Medicines, Inc. (RVMD)
CIK:        0001628171
Form:       8-K
Filed at:   2024-11-06T23:59:59+00:00
Accession:  0000950170-24-122266
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

RevMed Q3 net loss $156M; Phase 3 PDAC trial started, RMC-9805 initial data
---------------------------------------------------------------------------

- Net loss of $156.3M for Q3 2024 vs. $108.4M in Q3 2023; R&D expenses rose to $151.8M.
- Cash, equivalents and securities were $1.55B as of Sept 30, 2024; funding projected into 2027.
- Phase 3 RASolute 302 trial of RMC-6236 in metastatic PDAC dosed first patient; data event-driven.
- Initial RMC-9805 (KRAS G12D inhibitor) data show encouraging safety and antitumor activity; 1200 mg once daily candidate Phase 2 dose.
- FY 2024 GAAP net loss guidance reiterated at $560M-600M; NSCLC and combination data due in Q4 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1628171/000095017024122266/0000950170-24-122266-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1628171/000095017024122266/rvmd-20241106.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-122266

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer